Insider Selling: Castle Biosciences (NASDAQ:CSTL) COO Sells $426,257.28 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) COO Kristen Oelschlager sold 12,384 shares of Castle Biosciences stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $34.42, for a total value of $426,257.28. Following the completion of the transaction, the chief operating officer owned 72,649 shares in the company, valued at approximately $2,500,578.58. The trade was a 14.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Castle Biosciences Stock Down 2.2%

Shares of NASDAQ:CSTL opened at $33.50 on Friday. The company has a market capitalization of $1.02 billion, a PE ratio of -50.76 and a beta of 0.98. Castle Biosciences, Inc. has a 52-week low of $17.72 and a 52-week high of $44.28. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.85 and a current ratio of 6.04. The company has a fifty day moving average of $27.24 and a 200-day moving average of $25.47.

Castle Biosciences (NASDAQ:CSTL) last announced its earnings results on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.34. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%.The firm had revenue of $99.86 million for the quarter, compared to the consensus estimate of $86.23 million. On average, equities analysts predict that Castle Biosciences, Inc. will post -1.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Castle Biosciences

A number of large investors have recently made changes to their positions in the company. Global Retirement Partners LLC purchased a new stake in shares of Castle Biosciences in the second quarter worth $26,000. Federated Hermes Inc. purchased a new stake in Castle Biosciences during the fourth quarter valued at $26,000. Kemnay Advisory Services Inc. purchased a new stake in Castle Biosciences during the fourth quarter valued at approximately $35,000. Jones Financial Companies Lllp raised its holdings in Castle Biosciences by 10,592.0% during the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after buying an additional 2,648 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Castle Biosciences by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock worth $55,000 after purchasing an additional 297 shares during the period. 92.60% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

CSTL has been the subject of several research reports. Wall Street Zen upgraded shares of Castle Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. Weiss Ratings raised shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. BTIG Research boosted their price objective on Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. KeyCorp set a $35.00 price objective on Castle Biosciences in a research report on Friday, May 29th. Finally, Zacks Research downgraded Castle Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 26th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.